Literature DB >> 701801

Myeloma-induced immunosuppression: a multistep mechanism.

J A Katzmann.   

Abstract

Hosts of plasma cell tumors have a depressed primary antibody response. We have investigated the ability of cell homogenates and culture fluids from short-term cultures of spleen cells and tumor cells of mice bearing the MOPC-315 plasmacytoma to suppress the in vivo primary antibody response to sheep red blood cells. The homogenates and culture fluids of both MOPC-315 spleen cells and tumor cells suppress the antibody response in a dose-dependent manner. Culture fluids of spleen cells from tumor-bearing mice contain a 10,000- to 20,000-dalton immunosuppressive factor. Culture fluids of non-adherent tumor cells contain a high m.w. suppressor. Injection of the high m.w. tumor suppressive factor into normal mice induces the expression or appearance of host cells that secrete the 10,000- to 20,000-dalton immunosuppressor. The tumor suppressive factor, but not the spleen factor, causes an alteration of lymphocyte membranes such that the anti-DNP activity of the MOPC-315 myeloma protein can be detected on the circulating lymphocytes of injected mice.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 701801

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Deficiency in immunocompetence of mice cured from large MOPC-315 plasmacytomas by melphalan therapy.

Authors:  S Shoval; R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Mechanisms in secondary hypogammaglobulinaemia.

Authors:  P G Riches; J R Hobbs
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

3.  An immunosuppressive lipoprotein fraction from TEPC-183 bearing mice.

Authors:  L Wolfe; H F Havas; M R Fenton
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

4.  The mode of action of splenic suppressor cells in murine plasmacytoma.

Authors:  Y Chen; P Heller
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

5.  Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.

Authors:  M Laude; K L Russo; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.

Authors:  M S Khoory; M E Nesheim; E J Bowie; K G Mann
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

7.  Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).

Authors:  B S Wang; V Ruszala-Mallon; R E Wallace; R V Citarella; Y I Lin; F E Durr
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Suppressor activity of splenic macrophages in murine plasmacytoma (PC) is inhibited by PC specific ligands.

Authors:  Y H Chen; P Heller
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

9.  Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.

Authors:  R C Bocian; S Dray; S Ben-Efraim; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.